Ionis Pharmaceuticals
IONS
26.58
-0.64
-2.35%
Ionis Pharmaceuticals
US · IONS
#1749 by market cap
Listed 1970
26.58
-0.64
-2.35%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Recent news
-
Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $70Market Newswire · 2026/11/12
-
Rating change
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $87Market Newswire · 2026/10/21
-
Rating change
RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85Market Newswire · 2026/10/9
-
Company notice
Iondrive Ltd: Large-Scale Trials Validate Scalability of ION's TechnologyN/A · 2024/7/30
-
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $53 to $85Market Newswire · 2026/11/11
-
Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q3 Loss $0.66 a Share, Vs. FactSet Est of $1.23 LossMT Newswires · 2026/11/9
-
Rating change
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $85Market Newswire · 2026/9/25
-
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $41 to $100Market Newswire · 2026/11/10
-
Company notice
Liberta: Announcement that Family Service Eiko Co., Ltd. will hold a press conference for the first time in Tokyo to remove heavy metal ions, PFOS, and PFOA removal water server “swee,” which was jointly developed by Family Service Eiko Co., Ltd. with Shinshu UniversityJPX · 2025/4/11
-
Rating change
BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $54Market Newswire · 2026/9/24
-
Rating change
H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/26
-
Rating change
UBS Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $88Market Newswire · 2026/10/16
-
Rating change
Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/29
-
Rating change
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $79Market Newswire · 2026/10/20
-
Rating change
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and Abbott Laboratories (ABT)TipRanks · 2026/10/21
-
Rating change
CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85Market Newswire · 2026/10/30
-
Rating change
UBS Initiates Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $88Market Newswire · 2026/10/15
-
Company notice
Cacco: Ion's online market, "Green Beans", has adopted "O-PLUX" as a measure against credit card fraud.JPX · 2024/6/6
-
Rating change
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $91Market Newswire · 2026/10/9
-
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $66 to $104Market Newswire · 2026/10/22
-
Rating change
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $70 to $100Market Newswire · 2026/9/23
-
Rating change
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $84 to $100Market Newswire · 2026/9/24
-
Rating change
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)TipRanks · 2026/9/23
-
Rating change
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $70Market Newswire · 2026/9/22
-
Rating change
Goldman Sachs Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $56Market Newswire · 2026/9/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:59:29 · For reference only, not investment advice and not tailored to your situation.
Ionis Pharmaceuticals discussion 0 comments